WUXI APPTEC announces that its wholly-owned subsidiary has signed an agreement with Altaris to sell all shares of its cell therapy business units, Advanced Therapies and Oxford Genetics, in the USA and the United Kingdom. The company stated that this Trade will ensure uninterrupted services for customers and patients, and that relevant employees can continue to dedicate themselves to the company's mission. WUXI APPTEC emphasized that this divestment complies with the company's core criteria and will not have a significant impact on its performance and Operation condition, and that the other main Business departments of the company will maintain normal Operation, continuing to support Global innovative partners.
药明康德回应剥离部分海外业务：交易符合核心准则，其他业务不受影响
WUXI APPTEC responds to the divestment of part of its overseas Business: the Trade complies with core criteria, and Other businesses are unaffected.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated